| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 94.81% | Morgan Stanley | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight |
| 08/03/2022 | 94.81% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 08/03/2022 | -35.06% | Goldman Sachs | $4 → $2 | Maintains | Neutral |
| 07/14/2022 | 29.87% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 04/13/2022 | 62.34% | Goldman Sachs | $9 → $5 | Maintains | Neutral |
| 01/06/2022 | 159.74% | Morgan Stanley | → $8 | Initiates Coverage On | → Equal-Weight |
| 11/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/04/2021 | 224.68% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/13/2021 | 322.08% | Jefferies | → $13 | Initiates Coverage On | → Buy |
What is the target price for Nautilus Biotechnology (NAUT)?
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Morgan Stanley on August 3, 2023. The analyst firm set a price target for $6.00 expecting NAUT to rise to within 12 months (a possible 94.81% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nautilus Biotechnology (NAUT)?
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Morgan Stanley, and Nautilus Biotechnology reiterated their equal-weight rating.
When is the next analyst rating going to be posted or updated for Nautilus Biotechnology (NAUT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating Nautilus Biotechnology (NAUT) correct?
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a reiterated with a price target of $6.00 to $6.00. The current price Nautilus Biotechnology (NAUT) is trading at is $3.08, which is out of the analyst's predicted range.